Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
Alliance A021501
Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer
- NCT02839343 ↗
- Unknown
- Alliance for Clinical Trials in Oncology
- Standard
We haven't built an HCP commentary report on Alliance A021501 (mFOLFIRINOX and FOLFOX in Pancreatic Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Alliance A021501 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 18 | |
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Pancreatic Adenocarcinoma; Borderline Resectable Adenocarcinoma of the Head of the Pancrease
- Interventions
- radiation therapy; surgery; mFOLFIRINOX; FOLFOX
- Arms
- mFOLFIRINOX + surgery + FOLFOX · Experimental
- mFOLFIRINOX + radiation + surgery + FOLFOX · Experimental
- Enrollment
- 126
- Primary outcomes
- Overall Survival (OS) Rate
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI), Sky Foundation
- Start
- Dec 2016
- Primary completion
- Nov 30, 2020
- Results posted
- Yes
- Registry record
- NCT02839343 · updated May 24, 2022
Publications
linked from the registry- Snyder RA, Zemla TJ, Shi Q, Segovia D, Ahmad SA, O'Reilly EM, Herman JM, Katz MHG. Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501). Ann Surg Oncol. 2024 Oct;31(10):7033-7042. doi: 10.1245/s10434-024-15670-6. Epub 2024 Jul 15. PubMed 39008208
- Tchelebi LT, Segovia D, Smith K, Shi Q, Fitzgerald TJ, Chuong MD, Zemla TJ, O'Reilly EM, Meyerhardt JA, Koay EJ, Lowenstein J, Shergill A, Katz MHG, Herman JM. Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas. Int J Radiat Oncol Biol Phys. 2024 Sep 1;120(1):111-119. doi: 10.1016/j.ijrobp.2024.03.013. Epub 2024 Mar 15. PubMed 38492812
- Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, Ahmad S, Marsh R, Schwartz L, Behr S, Frankel WL, Collisson E, Leenstra J, Williams TM, Vaccaro G, Venook A, Meyerhardt JA, O'Reilly EM. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319. PubMed 35834226
- Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E; Alliance for Clinical Trials on Oncology. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017 Jul 27;17(1):505. doi: 10.1186/s12885-017-3441-z. PubMed 28750659